Abstract
Amniotic membranes (AMs) and corneas are critical materials in ocular surface reconstruction. AM has specific structures (e.g., basement and two types of cells with stemness characteristics: amniotic epithelial cells and amniotic mesenchymal cells), which contribute to its attractive physical and biological properties that make it fundamental to clinical application. The corneal endothelial cell is a vital part of the cornea, which can influence postoperative vision directly. However, widespread use of fresh AM and cornea has been limited due to their short use span and safety concerns. To overcome these concerns, different preservation methods have been introduced. Cryopreservation is distinguished from many preservation methods for its attractive advantages of prolonged use span, optimally retained tissue structure, and minimized infection risk. This review focuses on recent advances in cryopreserved AM and cornea, including different cryopreservation methods and their indications in ophthalmology.
The Challenge of Ocular Tissue Preservation
In ocular surgery, amniotic membranes (AM) and corneas represent the "holy grail" for reconstruction. However, the use of fresh tissue presents significant logistical and safety hurdles. Fresh tissue has an incredibly short shelf life and carries risks of viral transmission (e.g., HIV or Hepatitis) during the "window period" of initial screening. While alternative methods like lyophilization (freeze-drying) exist, they often compromise the tissue's extracellular matrix (ECM) and endogenous cells, stripping away the essential anti-inflammatory and anti-scarring properties. Cryopreservation bridges this gap by ensuring safety, long-term availability, and biological functionality.
Methodologies for Amniotic Membrane and Corneal Preservation
Preservation strategies are tailored to the specific structural requirements of the tissue. The AM is a complex multilayered structure consisting of an epithelium, a basement membrane, and a stroma (comprising compact, fibroblast, and spongy layers).
Amniotic Membrane (AM) Preservation
- Glycerol-cryopreservation: This is the standard clinical protocol, typically utilizing 50% glycerol at -80°C. It is highly effective at preserving histological structure and tensile strength, though it often results in reduced cell viability.
- DMSO-cryopreservation: Dimethyl Sulfoxide (DMSO) is used as an alternative cryoprotectant. Despite its higher toxicity compared to glycerol, it is significantly more effective at maintaining cell viability (often >80%), which is critical for regenerative applications.
Corneal Preservation
- Vitrification: This technique uses high concentrations of cryoprotectants to achieve a "glassy" state, preventing the formation of damaging ice crystals.
- Controlled Cooling: A "four-step cooling" process (e.g., 1.5~2°C/min down to -30°C, followed by acceleration) is employed to maintain the integrity of the corneal endothelium, which is essential for postoperative visual clarity.
Biophysical Insights and the "Viability Controversy"
The primary challenge in cryopreservation is managing the biophysical changes that occur during freezing. The formation of intracellular ice crystals is the "biggest enemy," as they can mechanically disrupt cell membranes. Furthermore, dehydration leads to solute effects that cause lipid peroxidation and protein denaturation, ultimately resulting in cell death.
A central debate in the field concerns whether tissue must remain "viable" to be clinically effective. While some argue that devitalized AM provides sufficient structural support, emerging evidence suggests that viable endogenous cells (AECs and AMSCs) provide superior angiogenic and anti-inflammatory signaling, accelerating wound healing. Notably, stromal cells in the AM appear more sensitive to freezing damage than epithelial cells, suggesting that protocols may need to be optimized based on the specific surgical requirement.
Clinical Efficacy and Long-term Outcomes
Cryopreservation has demonstrated significant success in clinical settings:
- Longevity: Cryopreserved AM can maintain over 70% cell viability after 24 months of storage at -80°C.
- Corneal Success: Glycerol-cryopreserved corneal grafts have shown transparency rates of 71% at one year and 58% after twelve years.
- Safety: In a study of 22 patients with corneal leukoma, glycerol-cryopreserved tissues resulted in zero graft rejections over a three-year follow-up.
- Innovation: Commercialized products like PROKERA—an "AM-in-a-ring" device—allow for sutureless AM therapy, functioning similarly to a biological contact lens.
Limitations and Future Perspectives
Despite its advantages, cryopreservation faces several hurdles. The need for deep-freeze facilities (-80°C to -196°C) is costly and limits accessibility in developing regions. Furthermore, the lack of a universal protocol leads to variability in clinical outcomes due to differences in cryoprotectant concentrations and cooling rates. High concentrations of cryoprotectants like DMSO or glycerol can also be endotoxic if not thoroughly removed before surgery.
Future research is focused on developing more "conducive" media that achieve the benefits of vitrification with reduced chemical toxicity, aiming for a more standardized and accessible global tissue banking system.
Summary updated